TW201613590A - Systems and methods for attenuating opioid-induced euphoria - Google Patents

Systems and methods for attenuating opioid-induced euphoria

Info

Publication number
TW201613590A
TW201613590A TW104130183A TW104130183A TW201613590A TW 201613590 A TW201613590 A TW 201613590A TW 104130183 A TW104130183 A TW 104130183A TW 104130183 A TW104130183 A TW 104130183A TW 201613590 A TW201613590 A TW 201613590A
Authority
TW
Taiwan
Prior art keywords
systems
methods
induced euphoria
attenuating
opioid
Prior art date
Application number
TW104130183A
Other languages
English (en)
Chinese (zh)
Inventor
Michele Hummel
Donald Kyle
Garth Whiteside
Original Assignee
Purdue Pharma Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Pharma Lp filed Critical Purdue Pharma Lp
Publication of TW201613590A publication Critical patent/TW201613590A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW104130183A 2014-09-12 2015-09-11 Systems and methods for attenuating opioid-induced euphoria TW201613590A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049989P 2014-09-12 2014-09-12
US201462065393P 2014-10-17 2014-10-17

Publications (1)

Publication Number Publication Date
TW201613590A true TW201613590A (en) 2016-04-16

Family

ID=55453711

Family Applications (1)

Application Number Title Priority Date Filing Date
TW104130183A TW201613590A (en) 2014-09-12 2015-09-11 Systems and methods for attenuating opioid-induced euphoria

Country Status (11)

Country Link
US (2) US20160074387A1 (cg-RX-API-DMAC7.html)
EP (1) EP3190890A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017526719A (cg-RX-API-DMAC7.html)
KR (1) KR20170052644A (cg-RX-API-DMAC7.html)
CN (1) CN107072204A (cg-RX-API-DMAC7.html)
AU (1) AU2015314714A1 (cg-RX-API-DMAC7.html)
CA (1) CA2961009A1 (cg-RX-API-DMAC7.html)
IL (1) IL251049A0 (cg-RX-API-DMAC7.html)
MA (1) MA40333A (cg-RX-API-DMAC7.html)
TW (1) TW201613590A (cg-RX-API-DMAC7.html)
WO (1) WO2016040934A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10745402B2 (en) 2017-01-02 2020-08-18 Purdue Pharma L.P. Morphinan derivatives and use thereof
KR20200022026A (ko) 2017-06-30 2020-03-02 퍼듀 퍼머 엘피 치료 방법 및 이의 약형
JP7293209B2 (ja) * 2017-10-20 2023-06-19 パーデュー、ファーマ、リミテッド、パートナーシップ 医薬剤形

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040209850A1 (en) * 2003-04-15 2004-10-21 Theraquest Biosciences, Llc Methods of treating pain and compositions for use therefor
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
WO2009120889A2 (en) * 2008-03-26 2009-10-01 Alltranz Inc. Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
WO2011109743A2 (en) * 2010-03-04 2011-09-09 Rand Jerry N Synergistic effects of combinations of buprenorphine and opioids for the treatment of pain
NZ628055A (en) * 2010-11-08 2016-03-31 Omeros Corp Treatment of addiction and impulse-control disorders using pde7 inhibitors
NZ631539A (en) * 2012-04-17 2016-10-28 Purdue Pharma Lp Systems and methods for treating an opioid-induced adverse pharmacodynamic response

Also Published As

Publication number Publication date
MA40333A (fr) 2016-03-17
JP2017526719A (ja) 2017-09-14
AU2015314714A1 (en) 2017-03-09
CN107072204A (zh) 2017-08-18
EP3190890A4 (en) 2018-04-25
CA2961009A1 (en) 2016-03-17
KR20170052644A (ko) 2017-05-12
US20160074387A1 (en) 2016-03-17
US20200276187A1 (en) 2020-09-03
IL251049A0 (en) 2017-04-30
EP3190890A1 (en) 2017-07-19
WO2016040934A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
ZA201804513B (en) Method of treating c3 glomerulopathy
PH12014502322A1 (en) Systems and methods for treating an opioid-induced adverse pharmacodynamic response
EP3016652A4 (en) Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors
IL244682A0 (en) Methods and systems for treatment by using intervention and providing tasks
EP3148640A4 (en) Systems and methods for peripheral nerve stimulation to treat tremor
EP3068353A4 (en) Systems and methods for subretinal delivery of therapeutic agents
PT4316555T (pt) Sistemas para administração de gás terapêutico
EP3013407A4 (en) Medical treatment system and method of use
IL241134B (en) Method and system for treating neuromotor system dysfunction
EP3157620A4 (en) Method and apparatus for neuromodulation treatments of pain and other conditions
EP3013416A4 (en) Systems and methods of delivering therapy using an ambulatory medical device
PH12017501393A1 (en) Methods and compositions for decreasing gastric emptying
EP3079766A4 (en) Meditation treatment device and method
IL248060A0 (en) System and method for therapeutic management of cough
SA515370011B1 (ar) طرق لعلاج سرطان باستخدام علاج توليفي من مركب داي هيدرو بيرازينو-بيرازين
EP3057985A4 (en) Systems and methods for determining a treatment course of action
MY175326A (en) Product and method for treating diarrhea
MA40333A (fr) Systèmes et méthodes pour atténuer une euphorie induite par des opioïdes
EP3024422A4 (en) Systems and methods for treatment of an airway disorder
PL3065751T3 (pl) Sposób leczenia raka i chorób współistniejących
MX2016016667A (es) Métodos para tratar el cáncer y prevenir la resistencia a fármacos contra el cáncer.
EP3044587A4 (en) Method of treating and prognosing scoliotic patient subgroups
IL240309B (en) A system and method for processing agricultural produce
PL3079495T3 (pl) Medykament i sposób leczenia chorób wrodzonej odpowiedzi immunologicznej
AU2013902004A0 (en) Compositions for Therapy and Methods of Treatment